Cargando…
Sunitinib Malate Synergistically Potentiates Anti-Tumor Effect of Gemcitabine in Human Bladder Cancer Cells
PURPOSE: Sunitinib malate (Sutent; Pfizer, New York, NY, USA) is a highly selective multi-targeted agent and has been reported to have potent anti-tumor effects against various tumors, including renal cell carcinoma and gastrointestinal stromal tumors. In this study, we explored in vitro the anti-tu...
Autores principales: | Yoon, Cheol Yong, Lee, Jung Sun, Kim, Bo Sun, Jeong, Seong Jin, Hong, Sung Kyu, Byun, Seok Soo, Lee, Sang Eun |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037508/ https://www.ncbi.nlm.nih.gov/pubmed/21344032 http://dx.doi.org/10.4111/kju.2011.52.1.55 |
Ejemplares similares
-
Synergistic Effect between Cisplatin and Sunitinib Malate on Human Urinary Bladder-Cancer Cell Lines
por: Arantes-Rodrigues, Regina, et al.
Publicado: (2013) -
Guillain-Barré Syndrome following Treatment with Sunitinib Malate
por: Kanaan, Ziad, et al.
Publicado: (2014) -
M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine
por: Tang, Zhiling, et al.
Publicado: (2022) -
NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014) -
Limited Expression of Cytochrome P450 17α-Hydroxylase/17,20-Lyase in Prostate Cancer Cell Lines
por: Jeong, Chang Wook, et al.
Publicado: (2011)